Payment overview · 2025
General Payments
$694.15
33 reported records · 17 companies
Healthcare provider profile · identity verified
Daniel G Paterson, MD
Allopathic & Osteopathic Physicians|Internal Medicine · GREENSBORO, NC · NPI 1497774178
Verified facts
What the public records show
CMS Open Payments records show Daniel G Paterson, MD received $694.15 in general payments during 2025 across 33 reported records.
Mayne Pharma Commercial LLC accounted for 17.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta, Yupelri.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 244 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 244 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Paxlovid by this doctor in 2024.
Viatris Specialty LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported YUPELRI as an associated drug or biological on 26927 records involving 11152 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Yupelri by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Mayne Pharma Commercial LLC | Unresolved — no canonical attribution shown | $124.04 | 17.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $69.73 | 10.1% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $64.39 | 9.3% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $57.83 | 8.3% | 4 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $53.09 | 7.7% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $50.85 | 7.3% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $45.74 | 6.6% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $44.43 | 6.4% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $34.54 | 5.0% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $28.45 | 4.1% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $20.78 | 3.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.73 | 2.7% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.75 | 2.6% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $16.43 | 2.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.37 | 2.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.25 | 2.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.75 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $694.15 | 33 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BIJUVA Normalized: bijuva |
Drug | Mayne Pharma Commercial LLC | $124.04 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $69.73 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $69.73 | 3 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $53.09 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $50.85 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $47.09 | 3 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $44.43 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $44.21 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $44.21 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $34.54 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $32.67 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $32.67 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $31.72 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $28.37 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $20.78 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.73 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $17.75 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $16.43 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.37 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $16.25 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $15.02 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 244 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 58 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 95 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 63 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| YUPELRI yupelri |
2025 | Yupelri | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
84 | 19 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
58 | 16 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
244 | 46 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
58 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
95 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
63 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
244 | 46 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
33 | 31 |
| Viatris Specialty LLC Exact reporting entity; no affiliate inference |
2025 | YUPELRI open payments reported associated product |
CMS Open Payments — General Payments 26927 supporting records · 11152 recipient NPIs · example record 1238463489 |
Yupelri · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 623 | 163 |
| Levothyroxine Sodium | Levothyroxine Sodium | 595 | 124 |
| Amlodipine Besylate | Amlodipine Besylate | 550 | 137 |
| Metoprolol Succinate | Metoprolol Succinate | 545 | 133 |
| Losartan Potassium | Losartan Potassium | 462 | 115 |
| Atorvastatin Calcium | Atorvastatin Calcium | 406 | 95 |
| Gabapentin | Gabapentin | 334 | 83 |
| Pantoprazole Sodium | Pantoprazole Sodium | 317 | 87 |
| Simvastatin | Simvastatin | 286 | 57 |
| Metformin Hcl Er | Metformin Hcl | 284 | 71 |
| Furosemide | Furosemide | 282 | 64 |
| Escitalopram Oxalate | Escitalopram Oxalate | 263 | 46 |
| Eliquis | Apixaban | 244 | 46 |
| Omeprazole | Omeprazole | 242 | 66 |
| Alprazolam | Alprazolam | 233 | 82 |
| Potassium Chloride | Potassium Chloride | 206 | 43 |
| Sertraline Hcl | Sertraline Hcl | 198 | 33 |
| Pravastatin Sodium | Pravastatin Sodium | 194 | 52 |
| Metoprolol Tartrate | Metoprolol Tartrate | 190 | 43 |
| Allopurinol | Allopurinol | 188 | 44 |
| Tramadol Hcl | Tramadol Hcl | 167 | 54 |
| Hydrochlorothiazide | Hydrochlorothiazide | 154 | 38 |
| Carvedilol | Carvedilol | 149 | 35 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 145 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 145 | 36 |
| Ezetimibe | Ezetimibe | 144 | 38 |
| Zolpidem Tartrate | Zolpidem Tartrate | 141 | 61 |
| Memantine Hcl | Memantine Hcl | 138 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 135 | 52 |
| Metformin Hcl | Metformin Hcl | 131 | 32 |
| Mirtazapine | Mirtazapine | 129 | 25 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 129 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 126 | 24 |
| Divalproex Sodium | Divalproex Sodium | 112 | 21 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 111 | 30 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 110 | 22 |
| Trazodone Hcl | Trazodone Hcl | 110 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 108 | 47 |
| Atenolol | Atenolol | 104 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 104 | 22 |
| Spironolactone | Spironolactone | 104 | 20 |
| Bupropion Hcl Sr | Bupropion Hcl | 98 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 95 | 33 |
| Lorazepam | Lorazepam | 95 | 40 |
| Meloxicam | Meloxicam | 95 | 30 |
| Mounjaro | Tirzepatide | 95 | 15 |
| Montelukast Sodium | Montelukast Sodium | 93 | 23 |
| Donepezil Hcl | Donepezil Hcl | 86 | 15 |
| Ipratropium Bromide | Ipratropium Bromide | 85 | 38 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 84 | 62 |
| Prednisone | Prednisone | 84 | 47 |
| Synthroid | Levothyroxine Sodium | 84 | 19 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 78 | 20 |
| Doxazosin Mesylate | Doxazosin Mesylate | 74 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 72 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 72 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 69 | 18 |
| Xarelto | Rivaroxaban | 69 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 65 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 63 | 39 |
| Ozempic | Semaglutide | 63 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 63 | 16 |
| Warfarin Sodium | Warfarin Sodium | 63 | 13 |
| Lisinopril | Lisinopril | 62 | 18 |
| Minoxidil | Minoxidil | 62 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 61 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 61 | 14 |
| Lovastatin | Lovastatin | 61 | 17 |
| Propranolol Hcl | Propranolol Hcl | 61 | 22 |
| Methocarbamol | Methocarbamol | 60 | 16 |
| Jardiance | Empagliflozin | 58 | 16 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 56 | 13 |
| Trulicity | Dulaglutide | 56 | suppressed |
| Torsemide | Torsemide | 55 | suppressed |
| Temazepam | Temazepam | 53 | suppressed |
| Verapamil Er | Verapamil Hcl | 53 | suppressed |
| Famotidine | Famotidine | 52 | 13 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 51 | 21 |
| Alendronate Sodium | Alendronate Sodium | 50 | 15 |
| Telmisartan | Telmisartan | 49 | 12 |
| Raloxifene Hcl | Raloxifene Hcl | 48 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 47 | 11 |
| Doxepin Hcl | Doxepin Hcl | 47 | 20 |
| Metoclopramide Hcl | Metoclopramide Hcl | 47 | 11 |
| Methimazole | Methimazole | 46 | suppressed |
| Myrbetriq | Mirabegron | 45 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 43 | 19 |
| Cefdinir | Cefdinir | 41 | 19 |
| Clonazepam | Clonazepam | 41 | 14 |
| Buspirone Hcl | Buspirone Hcl | 40 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 40 | suppressed |
| Novolog Flexpen | Insulin Aspart | 40 | 12 |
| Celecoxib | Celecoxib | 39 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 39 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 38 | 18 |
| Repatha Sureclick | Evolocumab | 38 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 37 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | 11 |
| Finasteride | Finasteride | 35 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | suppressed |
| Amoxicillin | Amoxicillin | 34 | 25 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | 12 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 34 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 34 | suppressed |
| Azithromycin | Azithromycin | 33 | 30 |
| Cilostazol | Cilostazol | 33 | suppressed |
| Lactulose | Lactulose | 33 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 33 | 31 |
| Diclofenac Sodium | Diclofenac Sodium | 32 | suppressed |
| Glimepiride | Glimepiride | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Digoxin | Digoxin | 31 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | 16 |
| Nitroglycerin | Nitroglycerin | 30 | 23 |
| Valsartan | Valsartan | 30 | suppressed |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 28 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 18 |
| Oxycodone Hcl | Oxycodone Hcl | 27 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 27 | suppressed |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 26 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 26 | 26 |
| Nebivolol Hcl | Nebivolol Hcl | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Fluconazole | Fluconazole | 24 | 11 |
| Tresiba Flextouch U-200 | Insulin Degludec | 24 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 23 | 13 |
| Tradjenta | Linagliptin | 23 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 22 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Praluent Pen | Alirocumab | 22 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 22 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 22 | suppressed |
| Creon | Lipase/Protease/Amylase | 21 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Invokana | Canagliflozin | 21 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 20 | 11 |
| Nystatin | Nystatin | 20 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 20 | 12 |
| Rizatriptan | Rizatriptan Benzoate | 20 | suppressed |
| Travoprost | Travoprost | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 16 |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | 12 |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Levemir Flexpen | Insulin Detemir | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | suppressed |
| Yupelri | Revefenacin | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Entacapone | Entacapone | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Klor-Con M20 | Potassium Chloride | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Metolazone | Metolazone | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 12 |
| Topiramate | Topiramate | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Anastrozole | Anastrozole | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 14 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Nyamyc | Nystatin | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Humira(Cf) Pen | Adalimumab | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 11 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Ertapenem | Ertapenem Sodium | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $694.15 · 33 records | Mayne Pharma Commercial LLC | BIJUVA, CAMZYOS, Cologuard Collection Kit, ELIQUIS, JARDIANCE, LEQVIO, MOUNJARO, NEXLETOL, NURTEC ODT, Ozempic, QULIPTA, REXULTI, Rybelsus, TEPEZZA, TRELEGY ELLIPTA, TZIELD, UBRELVY, VOQUEZNA, Wegovy, YUPELRI, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error